Background
Myopathy is a muscle disease unrelated to any disorder of innervation or neuromuscular junction. Etiologies vary widely. The common symptoms are muscle weakness, impaired function in activities of daily life, and, rarely, muscle pain and tenderness. Presence of discolored or dark urine suggests myoglobinuria.
For the emergency physician, it is important to distinguish neurologic from muscular dysfunction. However, in the face of profound weakness, establishing ABCs with attention to airway and aspiration precautions and providing supportive care are indicated while inpatient consultation and detailed studies are performed.
Pathophysiology
Most congenital myopathies or inherited myopathies are chronic slowly progressive diseases. The emergency physician rarely attends to a patient specifically to treat congenital myopathy unless acute deterioration occurs. Emergency physicians attend to patients with metabolic, inflammatory, endocrine, and toxic causes of myopathy more often than those with congenital causes because of the acute or subacute onset of symptoms associated with noncongenital forms.[1]
Periodic paralyses are a group of diseases that cause patients to present with acute weakness due to potassium shifts, leading to muscle dysfunction. A genetic defect of the sodium ion channel in muscle cell membranes is responsible for the paralysis, which may last from hours to days.
Epidemiology
Mortality/Morbidity
- Morbidity and mortality of myopathies is related to the etiology of the condition, severity of disease, and the presence of comorbid conditions.
- Severe weakness may lead to respiratory failure and death.
Race
Thyrotoxic hypokalemic periodic paralysis is known to occur in Asian men, and one study suggests that Polynesians are also at risk for this condition.[2]
Nance JR, Dowling JJ, Gibbs EM, Bönnemann CG. Congenital Myopathies: An Update. Curr Neurol Neurosci Rep. Mar 4 2012;[Medline].
Elston MS, Orr-Walker BJ, Dissanayake AM, Conaglen JV. Thyrotoxic, hypokalaemic periodic paralysis: Polynesians, an ethnic group at risk. Intern Med J. May 2007;37(5):303-7. [Medline].
Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. Oct 2009;22(5):506-15. [Medline].
Valiyil R, Christopher-Stine L. Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep. Jun 2010;12(3):213-20. [Medline]. [Full Text].
Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J. Apr 1999;75(882):193-7. [Medline].
Bennett JC, Plum F. Myopathies. In: Cecil Textbook of Medicine. 20th ed. WB Saunders Co; 1996:1500-03, 2158-73.
Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD. Harrison's Principles of Internal Medicine. 14th ed. McGraw-Hill; 1998:2473-2483.
Griggs RC, Ptacek LJ. The periodic paralyses. Hosp Pract (Off Ed). Nov 15 1992;27(11):123-6, 129-30, 136-7. [Medline].
Plate AM, Boyle BA. Musculoskeletal manifestations of HIV infection. AIDS Read. Feb 2003;13(2):62, 69-70, 72, 76. [Medline].
Riggs JE, Schochet SS, Joynt RJ, Griggs RC, eds. Muscle disease. In: Clinical Neurology. Vol 4. 1997:1-37.
Stedwell RE, Allen KM, Binder LS. Hypokalemic paralyses: a review of the etiologies, pathophysiology, presentation, and therapy. Am J Emerg Med. Mar 1992;10(2):143-8. [Medline].
Stobo JD, Hellman DB. Myopathies. In: The Principles and Practice of Medicine. 23rd ed. McGraw-Hill; 1996:898-904.
Tintinelli JE, Krome RL, Ruiz E. Emergency Medicine: A Comprehensive Study Guide. 4th ed. McGraw-Hill; 1996:1036.
Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol. Nov 2002;14(6):643-7. [Medline].
Print
